For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Scholar Rock, Inc.

USPTO Granted Patents = 34

EPO Patents = 13

Trademarks = 1

Forward Citations = 214

Loading Chart...

Loading Chart...

45 inventors (with patents filed for the assignee):

Michelle Marie Straub (21 out of 21 patents)

Thomas Schurpf (20 out of 20 patents)

Nagesh K Mahanthappa (14 out of 21 patents)

4. Justin W Jackson (12 out of 12 patents)

5. Abhishek Datta (10 out of 10 patents)

6. Stefan Wawersik (10 out of 10 patents)

7. Gregory John Carven (10 out of 20 patents)

8. Adriana Donovan (9 out of 12 patents)

9. Katherine Jane Turner (8 out of 16 patents)

10. Christopher Littlefield (7 out of 7 patents)

11. Caitlin Stein (6 out of 7 patents)

12. Matthew Salotto (6 out of 6 patents)

13. Dong Yun Lee (4 out of 4 patents)

14. Allan Capili (4 out of 4 patents)

15. Kevin B Dagbay (4 out of 4 patents)

Core Competencies:

Myostatin Antibodies

Growth Factor Modulation

TGF-beta Inhibitors

Isoform-Selective

Compositions

Therapies

Myopathy Treatment

Antibody Composition

34 patents: Sort by Forward Citations

1. 12753226 - TGFbeta1-BINDING IMMUNOGLOBULINS AND USE THEREOF (2026-10-06),

2. 12661400 - Methods of Treating Myopathies with Anti-Pro/Latent Myostatin Antibodies (2026-06-23),

3. 12582712 - Method of Making Anti-Pro/Latent Myostatin Antibodies (2026-03-24),

4. 12577296 - Compositions and methods for growth factor modulation (2026-03-17),

5. 12454570 - Compositions and methods for growth factor modulation (2025-10-28),

6. 12358992 - LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof (2025-07-15),

7. 12338279 - Selective and potent inhibitory antibodies of myostatin activation (2025-06-24),

8. 12297262 - RGMC-selective inhibitors and use thereof (2025-05-13),

9. 12281159 - TGFβ antibodies, methods and uses (2025-04-21),

10. 12252531 - Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitors (2025-03-18),

11. 12173059 - LTBP complex-specific inhibitors of TGFβ and uses thereof (2024-12-24),

12. 12122823 - Isoform-selective TGFB1 inhibitors and use thereof (2024-10-22),

13. 12006359 - Methods for altering body composition by administering anti-pro/latent myostatin antibodies (2024-06-11),

14. 11925683 - Compositions for making and using anti-Myostatin antibodies (2024-03-12),

15. 11827698 - Compositions and methods for growth factor modulation (2023-11-28),

Company Overview

Scholar Rock, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for serious diseases. The company specializes in harnessing its proprietary platform to target the activation of growth factors, which play a critical role in various biological processes. Scholar Rock's research primarily addresses conditions related to muscle and neuromuscular disorders, aiming to provide transformative treatment options that improve patient outcomes and enhance quality of life.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

34 Patents

#85 in Cambridge, MA

#606 in Massachusetts

#10,022 in US

#19,651 in the World

Cambridge, MA, United States of America

Scholar Rock, Inc.

Forward Citations = 214

45 inventors:

Michelle Marie Straub (21 out of 21 patents)

Thomas Schurpf (20 out of 20 patents)

Nagesh K Mahanthappa (14 out of 21 patents)

4. Justin W Jackson (12 out of 12 patents)

5. Abhishek Datta (10 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Scholar Rock, Inc.. Retrieved from https://idiyas.com/company/scholar-rock

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…